Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors
The Wnt-pathway has a critical role in development and tissue homeostasis and has attracted increased attention to develop anticancer drugs due to its aberrant activation in many cancers. In this study, we identified a novel small molecule series with a thienopyrimidine scaffold acting as a downstre...
Main Authors: | Cédric Boudou, Luce Mattio, Alexey Koval, Valentin Soulard, Vladimir L. Katanaev |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1045102/full |
Similar Items
-
Erratum: Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors
by: Frontiers Production Office
Published: (2023-03-01) -
Beyond TNBC: Repositioning of Clofazimine Against a Broad Range of Wnt-Dependent Cancers
by: Jiabin Xu, et al.
Published: (2020-12-01) -
A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent Cancers
by: Kamal Ahmed, et al.
Published: (2016-07-01) -
Countering Triple Negative Breast Cancer via Impeding Wnt/β-Catenin Signaling, a Phytotherapeutic Approach
by: Laleh Arzi, et al.
Published: (2022-08-01) -
Clofazimine: A journey of a drug
by: Jiabin Xu, et al.
Published: (2023-11-01)